The brain is the organ primarily affected by elevated phenylalanine (Phe) i
n the disease phenylketonuria (PKU). The hallmark neuropathology of both th
e untreated and treated PKU brains is hypomyelination or demyelination or b
oth. Because cognitive deficits are present in untreated and treated indivi
duals, the link between the observed neuropathology and cognitive deficits
is important to ascertain. Two current models of the molecular events under
lying the cognitive deficits are presented. The first model is based on the
hypothesis that cognitive deficits in individuals with PKU result from a d
eficiency of the neurotransmitter dopamine. Decreased levels of tyrosine in
the PKU brain are believed to cause the low levels of dopamine. The possib
le connections between reduced dopamine levels and the observed myelin defi
cits are presented. However, as discussed, the link between the two remains
elusive. The second model is based on the hypothesis that the primary insu
lt to the PKU brain is loss of myelin and that this secondarily leads to ne
uronal dysfunction. The function of myelin is reviewed, including evidence
showing that myelin and the axon communicate with one another to form a fun
ctional unit. Because the ability of the axon to conduct action potentials
at normal speed is compromised when myelin is not formed or is lost, the la
tter model has the capacity to account for both abnormalities and cognitive
deficits. Current studies characterizing the neuropathology of the recentl
y developed genetic mouse model for PKU, the PAH(enu2) mouse, are reviewed.
Preliminary evidence is summarized that indicates that Phe specifically in
hibits cholesterol metabolism in the oligodendrocyte, the cell that forms m
yelin in the brain. Finally, areas of future, high-priority research are ou
tlined. MRDD Research Reviews 1999;5:104-112. Published 1999 Wiley-Liss, In
c.dagger.